Pharmaceutical Federation (02268) continued to rise by more than 9%. As of press time, it rose 9.48% to HK$17.1, with a turnover of HK$1.89 million.
The Zhitong Finance App learned that Yao Ming United (02268) continued to rise by more than 9% and rose 9.48% to HK$17.1 at press time, with a turnover of HK$1.89 million.
According to the news, on March 15, it was learned on the official website of BIO, a well-known biotechnology organization in the US, that BIO revised and updated the content of a press release it issued on the 13th on March 14, US time: “BIO is currently taking measures to separate it from Pharmaceutical Kangde in terms of organizational membership” before the revision has been updated to “Pharmaceutical Kangde voluntarily terminates its BIO membership.”
According to Open Source Securities, Pharmaceutical Federation focuses on providing end-to-end CRDMO services for bioconjugated drugs to customers around the world. Its main business includes the discovery, process development, and GMP production of bioconjugated drugs, monoclonal antibody intermediates, and related ligands and payloads. The company has served a total of 304 customers worldwide, including most players in the global ADC and bioconjugate drug markets. In the short term, the number of customers served by the company increased rapidly. The amount of uncompleted orders reached US$411 million at the end of June 2023, providing a guarantee for high future performance growth. In the medium to long term, the number of research pipelines in the company continues to increase, and the number of high-value-added back-end projects continues to grow, which is expected to open up room for improvement in performance.